A Phase 2 clinical trial involving MT1013 Injection has reached completed status as of July 22, 2026. The study, registered as NCT06690242, evaluated MT1013 Injection for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. MT1013 is related to etelcalcetide, which carries approved regulatory status.
The trial title on record is "MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease." Its listed phase is Phase 2, and its current status is completed as of the date noted above.
No results, efficacy data, or safety findings have been provided alongside this status update. This brief reports only the trial's phase and completion status as recorded in the registry entry. Readers should not infer outcomes, benefits, or risks from the completion status alone, since no result data accompanies this update.
Further details on the trial, including any future results postings, may become available through the official registry listing. For additional context on etelcalcetide as a compound, readers can consult the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT06690242"]